Projects

HTTK toob kokku juhtivad psüühika, keha, sotsiaalse konteksti ja ruumilise konteksti uurijad, et luua distsipliinide ülene arusaam komplekssüsteemidest, mis mõjutavad heaolu: elu kvaliteeti erinevates valdkondades objektiivses ja eriti subjektiivses mõttes. Me käsitleme 4 uurimisvaldkonda. 1) KORRELAADID: Millised bio-psühholoogilised ja sotsiaal-ruumilised omadused on seotud heaolu püsivamate komponentidega nagu eluga rahulolu? 2) MEHHANISMID: Kuidas rulluvad inimestes lahti heaolu dünaamilised komponendid, näiteks emotsioonid? 3) ENESEHOOL: Kuidas inimesed ise oma heaolu enesehoole ökosüsteemides mõistavad ja juhivad? 4) SEKKUMISED: Kuidas heaolu isikustatud ja kohandatud sekkumistega edendada? HTTK rahastab interdistsiplinaarseid ametikohti; registriandmetega lõimitud longituud-uuring; doktorikooli; tippsündmusi; ja rändluse ja koostöö toetusmeedet. HTTK tõstab osalevate rühmade, asutuste ja Eesti heaoluteaduste tulemuslikkust ja mõjukust.

The project aims to revolutionise biosensors and point-of-care testing devices by developing sensor arrays using Molecularly Imprinted Polymers (MIPs) as biomimetic receptors for multiplex and/or simultaneous detection of targets that are of significant interest to clinical and environmental health. MIPs offer several advantages over traditional biological recognition elements in being more stable, cost-effective, and reproducible, making them ideal for low-cost and fast recognition of clinically relevant biomarkers and environmental pollutants in complex matrices. We will develop novel synthesis approaches for MIP-based sensor arrays that are affordable and scalable, allowing for the production of large quantities of sensors at low cost. Our innovative approach has the potential to establish a new generation of analytical tools that will significantly improve public health and safety, particularly in critical industries such as healthcare and environmental monitoring.

Synthetic receptors known as Molecularly Imprinted Polymers (MIPs) were engineered and combined with various sensing platforms to create fast and cost-effective analytical tools applicable for medical diagnostics and environmental monitoring. These MIPs were targeted towards clinically relevant proteins as well as emerging environmental pollutants such as antibiotics, and then integrated with piezoelectric or electrochemical portable transducers to create sensors capable of detecting the specified analytes. The resulting MIP-based sensors demonstrated the capability to quantitatively detect analytes within relevant concentration ranges, with rapid responses occurring within 15-20 minutes. Notable successes included the detection of neurotrophic factor proteins (BDNF and CDNF) as potential biomarkers of neurological disorders, as well as viral proteins (HCV-E2, N and S1 of SARS-CoV-2) for diagnosing hepatitis C and COVID-19. Additionally, the ability to detect antibiotics, including sulfamethizole and macrolides, in water at nanomolar concentrations was demonstrated. One of the most notable achievements was the development of prototype sensors for rapid detection of coronavirus antigens from patient samples. These sensors outperformed commercially available lateral-flow immunochromatography-based SARS-CoV-2 antigen tests in terms of their ability to determine the concentration of the virus proteins in the sample, as well as a noticeably lower detection limit, which potentially allows the detection of infection at an earlier stage. Potentially, MIP layer in these sensors can be quickly adapted to detect virtually any pathogen, thereby contributing to the development of rapid diagnostic tests to address new pandemics. Thus, the outcome of the project contributes significantly to the fabrication of affordable, precise, and rapid sensors suitable for point-of-care (PoCT) and infield applications, offering an alternative to expensive and labor-intensive methods.

A prototype allowing a rapid diagnostic possibility of COVID-19 has been developed. The principle of operation of the prototype differs drastically from widespread lateral flow COVID-19 express diagnostics tests currently available on the market. Namely, the prototype is a combination of sensor chip modified with the synthetic receptor and a portable potentiostat. The synthetic receptors were prepared by molecularly imprinting technology and targeted against nucleocapsid (N) and spike (S) SARS-CoV-2 viral proteins. It was shown that the prototype was capable of detecting the target proteins from patients’ nasopharyngeal samples in 15 min through measurement of the redox reaction intensity at the chip after its incubation in the mentioned sample. The prototype has the following advantages over lateral flow tests: (i) employment of the synthetic receptors as sensitive elements instead of their biological counterparts provides a more cost effective and stable diagnostics tool in whole; (ii) about hundredfold lower LOD allows diagnosis of COVID-19 at earlier stage; (iii) measurement of concentration of the proteins allows estimate viral load. Therefore, the prototype has the outstanding innovative potential for its further development to offer a reliable COVID-19 express diagnostic tool. Such a tool can be employed in clinical institutions for example in primary care physician practices, emergency medicine etc. The tool could be also developed for point-of-care and personal use at home as well in order to reduce load on healthcare systems and prevent additional risks for passing on the infection to other people. It should be noted that in this project we managed, for the first time to the best of our knowledge, to apply the molecular imprinting technology for detection of SARS-CoV-2 viral proteins. The results were published as a scientific paper in the top interdisciplinary journal devoted to biosensors, which has already received multiple citations.